It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
The company is eligible for 12 months exclusivity from launch
OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Deal signed with AOP Orphan for US commercial rights
A veteran in cell therapy and oncology commercialisation
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Nearly 6,000 patients have been treated with the drug since 2017
Subscribe To Our Newsletter & Stay Updated
